We are working in the public interest to hold pharmaceutical companies accountable. Your endorsement can make a difference.
Show your support for the Pharmaceutical Accountability Foundation
The Pharmaceutical Accountability Foundation acts in the public interest and strives to make overpriced drugs more affordable through legal actions that hold pharmaceutical companies accountable.
Complaint against Leadiant
For example, in 2018, Farma ter Verantwoording filed a complaint with the ACM about the excessive prices that pharmaceutical company Leadiant was charging for a pre-existing orphan drug. The ACM fined Leadiant €19.5 million for this in 2021.
Proceedings against AbbVie
In December 2021, the Pharmaceutical Accountability Foundation held one of the world’s largest biopharma companies, AbbVie, liable for the excessive (unfair) prices it charged for the drug Humira during the period it enjoyed patent protection.
Help us continue our work by making a donation and/or stay informed through our newsletter.
Statement of Support
I hereby express my sympathy and want to contribute to achieving the goal of the foundation, which is to make medicines and medical technologies affordable and accessible to everyone.
Interested in your organisation being added here? Contact us at email@example.com.
Committee of Recommendation
Our Committee of Recommendation exists of inspiring people and (academic) experts affiliated with the field of (access to) medicines and healthcare.
Em. Prof. Dr. André Knottnerus
Physician epidemiologist, former chair of the Health Council, and emeritus professor of family medicine at Maastricht University. He publishes regularly on the need to treat essential medicines and vaccines as global public goods.
Prisca Zwanikken, MD, M.Sc.CH, PhD
Senior public health expert, involved in capacity building of training and educational institutions in low- and middle-income countries. A long-time member of HAI, she is also involved in teaching Rational Drug Use
Em. Prof. Dr. Gerrit van der Wal, MD
Advisor and supervisor health care, former GP, emeritus professor of public health and former Inspector-General/CMO Netherlands.
Prof. Dr. Pim van Gool
Professor of Neurology at Public and Occupational Health Amsterdam UMC and former chair of the Health Council of the Netherlands.
Em. Prof. Dr. F.M. Haaijer-Ruskamp
Emertitus Professor Drug Use UMCG. Expertise on rational prescribing and drug use, with attention to both individual (e.g., decisions) and macro-level influences, such as policy, price, and pharma industry.
Gilles de Wildt
Associate Clinical Professor Global Health at University of Birmingham (UK) and General Practitioner (Primary care Physician).
Entrepeneur, pharmacist and former chair of the board of DSW health insurance organisation.
Godelieve van Heteren, MB, MD
Senior international health, governance and Performance Based Financing consultant. Former member Dutch Parliament (PvdA).
Data processing and conditions for signing
Clicking “hide name from public” means signing anonymously. Your name will not be displayed on the website. If necessary, it will only be shown confidentially before a court. Other entered data are visible.
The content of the above statement of support may be amended in the future to reflect the current state of affairs. If you want to be kept informed about this or if you want to change your signature, send an email to firstname.lastname@example.org.
We store your data in a database in accordance with AVG guidelines.